A Phase 2 interventional study of Prostate stereotactic body radiotherapy with whole gland boost and Prostate stereotactic body radiotherapy with DIL boost in Prostate Cancer and Prostate Adenocarcinoma, sponsored by University of Nebraska. Not yet recruiting at 1 site in United States. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University of Nebraska · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Prostatic Neoplasms by University of Nebraska — 8 open to participants now, 8 under way, none of them phase 3. Prostatic Neoplasms · University of Nebraska.
Among the 13 studies in Prostatic Neoplasms by University of Nebraska, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, and was the 10th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 13 studies in Prostatic Neoplasms by University of Nebraska are open now, in 1 country. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 30+ · Men only
University of Nebraska · Sites in United States
Ages 30+ · Men only
University of Nebraska · Sites in United States
Ages 19+ · Men only
University of Nebraska · Sites in United States
Ages 19–110 · Healthy volunteers
University of Nebraska · Sites in United States
Ages 19+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 19 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8
First in 2004; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 54 across the 11 interventional studies, 500,010 across the 2 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Nebraska is the lead sponsor of 496 studies on the registry; 66 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 53 (64%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Prostatic Neoplasms by University of Nebraska, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
This is a phase 2 randomized clinical trial evaluating two dose escalation strategies during prostate stereotactic body radiotherapy (SBRT). A total of 160 patients with prostate adenocarcinoma will be enrolled and randomized in a 1:1 ratio to one of two treatment arms.
160 patients will be enrolled in this study over 3.2 years. Eligible participants will be stratified by risk group and tamsulosin use and randomized to one of two treatment arms. Both arms will receive 3625 cGy to the prostate plus planning margin delivered over 5 fractions. Arm A will receive an additional boost of 4000 cGy to the prostate alone. Arm B will receive an additional boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Acute and chronic GU and GI toxicities will be measured, as well as biochemical progression-free survival. Toxicities will be measured using CTCAE, Radiation Therapy Oncology Group, and Expanded Prostate Cancer Index Composite domains.
Participants will be followed for up to 5 years after completion of treatment.
The criteria were revised on the registry on Nov 3, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to Arm A will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4000 cGy to the clinical target volume (CTV), consisting of the prostate alone without a margin. Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB).
Radiation: Prostate stereotactic body radiotherapy with whole gland boost
Participants assigned to Arm B will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB).
Radiation: Prostate stereotactic body radiotherapy with DIL boost
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion.
Grade 2 or Higher Acute Genitourinary Toxicity
To evaluate acute genitourinary (GU) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using Common Terminology Criteria for Adverse Events Version 6.0 (CTCAE)
Time frame: From end of treatment to 3 months post-treatment
Grade 2 or Higher Acute Gastrointestinal Toxicity
To evaluate gastrointestinal (GI) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using CTCAE
Time frame: From end of treatment to 3 months post-treatment
Biochemical Progression-Free Survival
Time from initiation of study treatment to biochemical disease progression or death from any cause
Time frame: From initiation of study treatment to 5 years post-treatment
Chronic Gastrointestinal Toxicity - Cumulative Incidence
Cumulative incidence of chronic gastrointestinal (GI) toxicities assessed using CTCAE, Radiation Therapy Oncology Group (RTOG), and Expanded Prostate Cancer Index Composite (EPIC) domains.
Time frame: From 6 months to 21 months post-treatment
Chronic Genitourinary Toxicity - Cumulative Incidence
Cumulative incidence of chronic genitourinary (GU) toxicities assessed using CTCAE, RTOG, and EPIC domains.
Time frame: From 6 months to 21 months post-treatment
Chronic Gastrointestinal Toxicity
To evaluate chronic GI toxicities at 5 years using CTCAE, RTOG, and EPIC domains.
Time frame: At 5 years
Chronic Genitourinary Toxicity
To evaluate chronic GU toxicities at 5 years using CTCAE, RTOG, and EPIC domains.
Time frame: At 5 years
Start is estimated for Dec 2026; primary completion for Dec 2032, 72 months later.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 72 months is above that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start Jul 2026 → Dec 2026, primary completion Aug 2032 → Dec 2032 and completion Aug 2035 → Dec 2035.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.